{
    "Patient Information": {
        "Patient ID": "1947",
        "Patient Name": "Christina Ingram",
        "Date of Birth": "1960-09-01",
        "Age": 64,
        "Gender": "Male",
        "Contact Information": "N/A",
        "Address": "N/A"
    },
    "Diagnosis Information": {
        "Diagnosis Center": "N/A",
        "Doctor Name": "Dr. Melanie Ochoa",
        "Accession Number": "N/A",
        "Date of Diagnosis": "N/A",
        "Date of Report Issuance": "N/A",
        "CLIA Number": "N/A",
        "Laboratory Medical Director ": "N/A",
        "Method of Analysis": [
            "IHC",
            "Seq",
            "NGS"
        ],
        "Pipeline Version (Report Version)": "N/A"
    },
    "Cancer Information": {
        "Cancer Type": "Squamous cell carcinoma",
        "Cancer Stage": "Not explicitly stated",
        "Cancer Grade": "Not explicitly stated",
        "Cancer Location in the Body": "Lung",
        "Tumor Specimen Source": "Bronchus",
        "Tumor Percentage in Sample": "N/A",
        "Normal Specimen Source": "N/A",
        "Date of Tumor Sample Collection": "2023-05-19",
        "Date Tumor Sample Received": "2023-05-20",
        "Date of Normal Sample Collection": "N/A",
        "Date Normal Sample Received": "N/A"
    },
    "Biomarkers": {
        "General Biomarkers": {
            "Microsatellite Instability (MSI)": "High",
            "Tumor Mutational Burden (TMB)": "15 mutations/Mb High",
            "Tumor Mutational Burden Percentile": "N/A",
            "Loss of Heterozygosity (LOH)": "High - 22% of tested genomic segments exhibit LOH",
            "Mismatch Repair (MMR) Status": [
                "Positive| 3+, 71%"
            ],
            "PDL1 Expression": [
                "Positive| 1+, 88%"
            ],
            "EBV (Epstein-Barr Virus) Status": "N/A",
            "Other Immunotherapy Markers": "N/A",
            "Low-Coverage Regions (Indeterminate Genes)": [
                "FLT3",
                "ARHGAP45",
                "NT5C2",
                "PAX5",
                "XPC"
            ]
        },
        "Gene Mutations": [
            {
                "Gene Name": "SMO",
                "DNA Mutation Description": "c.1924A>C",
                "Protein Variant": "p.N713_A714insKGKGGG",
                "Mutation Effect": "N/A",
                "Functional Impact": "N/A",
                "Exon Number": 15,
                "Variant Allele Fraction": "30.25",
                "Transcript ID": "N/A",
                "Somatic or Germline": "N/A",
                "Potentially Actionable or Biologically Relevant": "N/A",
                "Analyte": "DNA tumor",
                "Method of Detection ": "Seq",
                "Pathogenicity": "Pathogenic",
                "Pertinent Negative Results": "N/A"
            },
            {
                "Gene Name": "APC",
                "DNA Mutation Description": "c.4800C>G",
                "Protein Variant": "p.I1600M",
                "Mutation Effect": "N/A",
                "Functional Impact": "N/A",
                "Exon Number": 6,
                "Variant Allele Fraction": "25.67",
                "Transcript ID": "N/A",
                "Somatic or Germline": "N/A",
                "Potentially Actionable or Biologically Relevant": "N/A",
                "Analyte": "DNA tumor",
                "Method of Detection ": "Seq",
                "Pathogenicity": "Likely Pathogenic",
                "Pertinent Negative Results": "N/A"
            },
            {
                "Gene Name": "RNF43",
                "DNA Mutation Description": "c.1354A>G",
                "Protein Variant": "p.N452D",
                "Mutation Effect": "N/A",
                "Functional Impact": "N/A",
                "Exon Number": 7,
                "Variant Allele Fraction": "8.5",
                "Transcript ID": "N/A",
                "Somatic or Germline": "N/A",
                "Potentially Actionable or Biologically Relevant": "N/A",
                "Analyte": "DNA tumor",
                "Method of Detection ": "Seq",
                "Pathogenicity": "Benign",
                "Pertinent Negative Results": "N/A"
            },
            {
                "Gene Name": "BRAF",
                "DNA Mutation Description": "c.427T>C",
                "Protein Variant": "p.*143Qext*31",
                "Mutation Effect": "N/A",
                "Functional Impact": "N/A",
                "Exon Number": 10,
                "Variant Allele Fraction": "20.11",
                "Transcript ID": "N/A",
                "Somatic or Germline": "N/A",
                "Potentially Actionable or Biologically Relevant": "N/A",
                "Analyte": "DNA tumor",
                "Method of Detection ": "Seq",
                "Pathogenicity": "Pathogenic",
                "Pertinent Negative Results": "N/A"
            },
            {
                "Gene Name": "SRSF2",
                "DNA Mutation Description": "c.394_395delinsGT",
                "Protein Variant": "p.R132C",
                "Mutation Effect": "N/A",
                "Functional Impact": "N/A",
                "Exon Number": 13,
                "Variant Allele Fraction": "6.12",
                "Transcript ID": "N/A",
                "Somatic or Germline": "N/A",
                "Potentially Actionable or Biologically Relevant": "N/A",
                "Analyte": "DNA tumor",
                "Method of Detection ": "Seq",
                "Pathogenicity": "Benign",
                "Pertinent Negative Results": "N/A"
            }
        ],
        "Immunochemistry Biomarkers": [
            {
                "Biomarker Name": "ER",
                "Number of Stained Cells": "N/A",
                "Percentage of Expression": "2+, 11%",
                "Interpretation": "Positive"
            },
            {
                "Biomarker Name": "PTEN",
                "Number of Stained Cells": "N/A",
                "Percentage of Expression": "1+, 48%",
                "Interpretation": "Positive"
            },
            {
                "Biomarker Name": "MSH6",
                "Number of Stained Cells": "N/A",
                "Percentage of Expression": "2+, 96%",
                "Interpretation": "Positive"
            },
            {
                "Biomarker Name": "PMS2",
                "Number of Stained Cells": "N/A",
                "Percentage of Expression": "1+, 48%",
                "Interpretation": "Positive"
            },
            {
                "Biomarker Name": "ERBB2",
                "Number of Stained Cells": "N/A",
                "Percentage of Expression": "2+, 61%",
                "Interpretation": "Positive"
            },
            {
                "Biomarker Name": "PD-L1(SP142)",
                "Number of Stained Cells": "N/A",
                "Percentage of Expression": "3+, 46%",
                "Interpretation": "Negative"
            }
        ]
    },
    "Therapeutic Information": {
        "FDA-Approved Therapies for Current Diagnosis": [
            {
                "Therapy Name": "abemaciclib, palbociclib, ribociclib, endocrine, therapy, everolimus",
                "Therapy Type": "targeted therapy",
                "Evidence Source": "N/A",
                "Associated Biomarker": {
                    "Biomarker Name": "ER",
                    "Biomarker level": "level 2",
                    "Positively/Negatively Associated": "BENEFIT"
                }
            },
            {
                "Therapy Name": "abemaciclib, palbociclib, ribociclib, endocrine therapy",
                "Therapy Type": "targeted therapy",
                "Evidence Source": "N/A",
                "Associated Biomarker": {
                    "Biomarker Name": "PR",
                    "Biomarker level": "level 2",
                    "Positively/Negatively Associated": "BENEFIT"
                }
            },
            {
                "Therapy Name": "pembrolizumab",
                "Therapy Type": "immunotherapy",
                "Evidence Source": "N/A",
                "Associated Biomarker": {
                    "Biomarker Name": "TMB",
                    "Biomarker level": "level 2",
                    "Positively/Negatively Associated": "BENEFIT"
                }
            },
            {
                "Therapy Name": "trastuzumab, ado-trastuzumab emtansine, pertuzumab, fam-trastuzumab deruxtecan-nxki, lapatinib, neratinib, tucatinib",
                "Therapy Type": "targeted therapy",
                "Evidence Source": "N/A",
                "Associated Biomarker": {
                    "Biomarker Name": "ERBB2",
                    "Biomarker level": "level 1",
                    "Positively/Negatively Associated": "LACK OF BENEFT"
                }
            }
        ],
        "FDA-Approved Therapies for Other Indications": []
    },
    "Clinical Trials": [
        {
            "Trial Title": "Anti hormonal therapy",
            "Clinical Trial ID": "N/A",
            "Phase of Trial": "N/A",
            "Trial Location": "N/A",
            "Therapy Type": "Chemotherapy",
            "Medication": "anastrazole, letrozole, exemestane, fulvestrant, tamoxifen, goserelin, leuprolide",
            "Associated Mutations": [
                "ER"
            ]
        },
        {
            "Trial Title": "Anti hormonal therapy",
            "Clinical Trial ID": "N/A",
            "Phase of Trial": "N/A",
            "Trial Location": "N/A",
            "Therapy Type": "Chemotherapy",
            "Medication": "anastrazole, letrozole, exemestane, fulvestrant, tamoxifen, goserelin, leuprolide",
            "Associated Mutations": [
                "PR"
            ]
        },
        {
            "Trial Title": "Anti inflammatory agents",
            "Clinical Trial ID": "N/A",
            "Phase of Trial": "N/A",
            "Trial Location": "N/A",
            "Therapy Type": "Chemotherapy",
            "Medication": "aspirin",
            "Associated Mutations": [
                "PIK3CA"
            ]
        },
        {
            "Trial Title": "Akt inhibitors",
            "Clinical Trial ID": "N/A",
            "Phase of Trial": "N/A",
            "Trial Location": "N/A",
            "Therapy Type": "Targeted therapy",
            "Medication": "AZD5363, MK-2206, ipataserib",
            "Associated Mutations": [
                "ARID1A"
            ]
        },
        {
            "Trial Title": "immunomodulatory agents",
            "Clinical Trial ID": "N/A",
            "Phase of Trial": "N/A",
            "Trial Location": "N/A",
            "Therapy Type": "Targeted therapy",
            "Medication": "avelumab, atezolizumab, durvalumab, ipilimumab, nivolumab, pembrolizumab",
            "Associated Mutations": [
                "TMB"
            ]
        },
        {
            "Trial Title": "PARP inhibitors",
            "Clinical Trial ID": "N/A",
            "Phase of Trial": "N/A",
            "Trial Location": "N/A",
            "Therapy Type": "Targeted therapy",
            "Medication": "BGB-290, BMN-673, olaparib, rucaparib, talazoparib",
            "Associated Mutations": [
                "NBN"
            ]
        },
        {
            "Trial Title": "Akt/mTor inhibitors",
            "Clinical Trial ID": "N/A",
            "Phase of Trial": "N/A",
            "Trial Location": "N/A",
            "Therapy Type": "Targeted therapy",
            "Medication": "AZD5363, BYL719, MK-2206, ipataserib, everolimus, temsirolimus",
            "Associated Mutations": [
                "PIK3CA"
            ]
        }
    ],
    "Variants of Unknown Significance (VUS)": [
        {
            "Gene Name": "TLR8",
            "DNA Alteration": "c.1394G>A",
            "Protein Variant": "p.R465H",
            "Mutation Effect": "N/A",
            "Variant Allele Fraction": "8.68",
            "Exon Number": 6,
            "Transcript ID": "N/A",
            "Functional Impact": "N/A",
            "Somatic or Germline": "N/A"
        },
        {
            "Gene Name": "ALK",
            "DNA Alteration": "G",
            "Protein Variant": "p.A34V",
            "Mutation Effect": "N/A",
            "Variant Allele Fraction": "20.1",
            "Exon Number": 17,
            "Transcript ID": "N/A",
            "Functional Impact": "N/A",
            "Somatic or Germline": "N/A"
        },
        {
            "Gene Name": "H3.3",
            "DNA Alteration": "A",
            "Protein Variant": "p.A374E",
            "Mutation Effect": "N/A",
            "Variant Allele Fraction": "3.21",
            "Exon Number": 2,
            "Transcript ID": "N/A",
            "Functional Impact": "N/A",
            "Somatic or Germline": "N/A"
        }
    ],
    "Additional Indicators": []
}